Under a tenth of individuals that would benefit from GLP-1 drugs like Wegovy have access to them, states the World Health Organization as it releases its initial guidance on the therapies.
Given over a billion individuals worldwide now obese, it is calling for increased and just availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a long-term condition that can be managed with holistic and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to broad access to the jabs that can help people shift substantial body mass, says the body.
GLP-1 Therapy Scarcity
Despite the present most favorable outlook, the production of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, per the WHO.
The advice urges countries and companies to increase access, by approaches such as voluntary licensing.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
How Weight-Loss Jabs Function
These medications mimick a body's own hormone to slow digestion, reduce hunger and enhance satiety so users reduce food intake.
People usually see weight reduction within a few weeks of beginning the weekly injections.
Studies suggests patients may see weight return after a year of discontinuing the drug, as their typical appetite resume.
Being carrying excess weight increases your risk for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the health agency.
